Just over three years, Polyphor's initial public offering in Switzerland raised CHF165m. Now, with just enough cash to get through the third quarter, it has been saved by a deal with US biotech EnBiotix.
Struggling Swiss biotech Polyphor AG, which has suffered a string of setbacks in the clinic, has been handed a lifeline by negotiating a merger with EnBiotix, Inc. of the US, a privately held rare disease company, which is focused on cystic fibrosis.
The proposed deal with Enbiotix comes at the end of what Polyphor chairman Kuno Sommer described as "an extensive and thorough review of a full range of strategic options," which...
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
The French drugmaker is expanding its neurology activities with the $470m deal.
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.
Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.
